Reyedar

Sections Diagnostics
Funding π°
Total β¬3M
Select investors Cottonwood Technology Fund, NV NOM, Pupil Labs, Uneti Ventures, Blue Sparrows MedTech Fund
Key people π§βπ€βπ§
- Alessandro Grillini - Co-founder & CEO/CTO
- Camiel van Vught - Co-founder & Commercial Director
- Carlo Enrico Petrillo - Lead Data Scientist & Technical Product Manager
Highlights β
- Solving the problem: As the aging population grows rapidly, the number of people with degenerative diseases such as Glaucoma, Parkinson's, and Multiple Sclerosis increases. Screening methods for these diseases are often invasive, unreliable, and time-consuming, leading to pressure on the healthcare system. Reyedar's technology solves this problem by detecting early symptoms within minutes in a non-invasive way. Combining deep learning with eye-tracking sensors on a user-friendly device, the company improves treatment outcomes and decreases healthcare costs.
- Big addressable market: As the aging population grows rapidly, the prevalence of degenerative diseases such as Glaucoma, Parkinson's, and Multiple Sclerosis increases. Glaucoma alone affects 80 million individuals, and this number is projected to rise to 120 million by 2040. Aside from the impact on the well-being of those affected, these diseases also impose a financial burden of over $25 billion annually on global society.
- The setup: Reyedar's setup includes lightweight glasses frames with eye tracking sensors, 64 corrective lenses with easy magnetic attachment, custom-made all-in-one PC with dedicated NVIDIA GPU, 27-inch monitor calibrated for luminance consistency, and cloud software platform for wireless and remote operating. π
Last update: July 18, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more